|
Jahrsdorfer, Bernd; Blackwell, Sue E; Wooldridge, James E et al. (2006) B-chronic lymphocytic leukemia cells and other B cells can produce granzyme B and gain cytotoxic potential after interleukin-21-based activation. Blood 108:2712-9
|
|
Jahrsdorfer, Bernd; Wooldridge, James E; Blackwell, Sue E et al. (2005) Immunostimulatory oligodeoxynucleotides induce apoptosis of B cell chronic lymphocytic leukemia cells. J Leukoc Biol 77:378-87
|
|
Jahrsdorfer, B; Wooldridge, J E; Blackwell, S E et al. (2005) Good prognosis cytogenetics in B-cell chronic lymphocytic leukemia is associated in vitro with low susceptibility to apoptosis and enhanced immunogenicity. Leukemia 19:759-66
|
|
Jahrsdorfer, Bernd; Blackwell, Sue E; Weiner, George J (2005) Phosphorothyoate oligodeoxynucleotides block nonspecific binding of Cy5 conjugates to monocytes. J Immunol Methods 297:259-63
|
|
Jahrsdorfer, Bernd; Blackwell, Sue E; Wooldridge, James E et al. (2005) Serum alters the uptake and biologic activity of CpG oligodeoxynucleotides in B cell chronic lymphocytic leukemia. Oligonucleotides 15:51-9
|
|
van Ojik, Heidi H; Bevaart, Lisette; Dahle, Christopher E et al. (2003) CpG-A and B oligodeoxynucleotides enhance the efficacy of antibody therapy by activating different effector cell populations. Cancer Res 63:5595-600
|
|
Jahrsdorfer, Bernd; Weiner, George J (2003) Immunostimulatory CpG oligodeoxynucleotides and antibody therapy of cancer. Semin Oncol 30:476-82
|
|
Jahrsdorfer, B; Hartmann, G; Racila, E et al. (2001) CpG DNA increases primary malignant B cell expression of costimulatory molecules and target antigens. J Leukoc Biol 69:81-8
|
|
Ballas, Z K; Krieg, A M; Warren, T et al. (2001) Divergent therapeutic and immunologic effects of oligodeoxynucleotides with distinct CpG motifs. J Immunol 167:4878-86
|
|
Weiner, G J (2000) The immunobiology and clinical potential of immunostimulatory CpG oligodeoxynucleotides. J Leukoc Biol 68:455-63
|
